Another study demonstrated the potential of discontinuing insulin therapy when DMR and glucagon-like peptide-1 receptor agonist were administered simultaneously to patients with type 2 diabetes, who were already using insulin.[41] Two meta-analyses[25,42] regarding the metabolic influences of endoscopic DMR have been published but de Oliveira GHP et al enrolled duplicated poster[43] from REVITA-2 trial[19] while the other included a trial focusing on insulin resistant women with polycystic ovary syndrome[44] rendering the selection bias in their interpretation. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.